论文部分内容阅读
目的分析利拉鲁肽与胰岛素泵治疗非初诊2型糖尿病的临床疗效。方法 60例非初诊2型糖尿病患者,分为观察组和对照组,各30例。对照组使用胰岛素泵治疗,观察组加用利拉鲁肽治疗。比较两组治疗前后的体重、血糖、胰岛细胞功能、氧化应激水平变化及不良反应。结果治疗后,两组的血糖均显著降低(P<0.05),且均达标;观察组治疗后体质量指数(BMI)和腰臀比显著降低(P<0.05),而对照组治疗前后BMI和腰臀比无显著变化(P>0.05);两组胰岛β细胞功能升高(P<0.05),且观察组高于对照组的(P<0.05);两组氧化应激水平降低(P<0.05),且观察组低于对照组(P<0.05);观察组的不良反应发生率高于对照组(P<0.05)。结论对于非初诊2型糖尿病患者,利拉鲁肽联合胰岛素泵治疗可显著改善患者的体重、胰岛细胞功能及氧化应激状态,但不良反应较大,临床应根据患者是否耐受及经济等综合情况合理选择。
Objective To analyze the clinical efficacy of liraglutide and insulin pump in the treatment of non-newly diagnosed type 2 diabetes mellitus. Methods Sixty non-newly diagnosed type 2 diabetic patients were divided into observation group and control group, with 30 cases in each group. Control group using insulin pump treatment, observation group plus liraglutide treatment. The body weight, blood glucose, islet cell function, oxidative stress level and adverse reactions in both groups before and after treatment were compared. Results After treatment, the blood sugar of both groups were significantly decreased (P <0.05), and both reached the standard. Body mass index (BMI) and waist-hip ratio were significantly decreased in the observation group after treatment (P <0.05) (P> 0.05). The function of islet β cell in both groups was increased (P <0.05), and the observation group was higher than that in the control group (P <0.05). The levels of oxidative stress in the two groups were decreased (P < 0.05), and the observation group was lower than the control group (P <0.05). The incidence of adverse reactions in the observation group was higher than that in the control group (P <0.05). Conclusion For patients with newly diagnosed type 2 diabetes, liraglutide and insulin pump therapy can significantly improve the patient’s body weight, islet cell function and oxidative stress status, but the adverse reactions are large, the clinical should be based on whether the patient’s tolerance and economic and other comprehensive Reasonable choice.